alexa Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Diabetes & Endocrinology

Diabetes & Endocrinology

Journal of Steroids & Hormonal Science

Author(s): Andreoli CM, Miller JW

Abstract Share this page

Abstract PURPOSE OF REVIEW: Recent research has shown that vascular endothelial growth factor (VEGF) is responsible for many ocular pathologies involving neovascularization. Over the past several years several new agents targeting VEGF have become commercially available for intraocular use. These agents have revolutionized the care of neovascular age related macular degeneration and have great potential for other blinding conditions such as diabetic retinopathy, retinopathy of prematurity, and neovascular glaucoma. RECENT FINDINGS: The VEGF Inhibition Study in Ocular Neovascularization (VISION) trial first showed that an anti-VEGF agent (pegaptanib) was able to prevent vision loss in neovascular age related macular degeneration. The Minimally Classic/Occult Trial of Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) trials showed that ranibizumab prevented moderate vision loss in neovascular age related macular degeneration and for the first time that a substantial proportion of patients regained vision. Smaller case series have shown that bevacizumab can regress retinal, iris and disc neovascularization. Ongoing trials are investigating the utility of anti-VEGF therapy in retinopathy of prematurity, diabetic retinopathy, and neovascular glaucoma. SUMMARY: Newer anti-VEGF therapies have shown unprecedented efficacy in treating age related macular degeneration with many patients experiencing improvement in vision. Ongoing trials will help guide their use in age related macular degeneration and expand their indications to many other blinding diseases. This article was published in Curr Opin Ophthalmol and referenced in Journal of Steroids & Hormonal Science

Relevant Expert PPTs

Relevant Speaker PPTs

  • Xavier Guerrero-Pich
    PPT Version | PDF Version
  • Alessandro Pini
    A novel synthetic antimicrobial peptide for the cure of gram-negative infections: Mechanism of action, efficacy in vivo, toxicity, bio-distribution and resistance selection
    PPT Version | PDF Version
  • K Mulkijanyan
    Plant biopolymers from Boraginaceae family species and their synthetic derivatives: Prospective pharmacological agents
    PPT Version | PDF Version
  • Manoj Kumar Chhikara
    How promising is the development of a semi-synthetic meningococcal conjugate vaccine ?
    PDF Version
  • Jianbo Wang
    Transcriptome and small RNA gene expression changes in synthetic allohexaploids of
    PPT Version | PDF Version
  • Werner Lottermoser
    Application of a Difference Electron Nanoscope (DEN): Correlation between 3D Magnetical Structures of Synthetic Fayalite with Synchrotron and Neutron Diffraction and Mössbauer Spectroscopy
    PPT Version | PDF Version
  • Jianping Yu
    Photosynthetic Ethylene Production in a Cyanobacterium
    PDF Version
  • Murad H. Al-Salamat
    Design of small synthetic molecules that mimic IL-4 binding to IL-4Rα, which therefore promotes alternate macrophage differentiation (M2) with minimal effect on the endothelial and vascular IL-4Rα.
    PDF Version

Recommended Conferences

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version